Anti-infectives — Revenue
Zoetis Anti-infectives — Revenue decreased by 15.1% to $241.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.2%, from $249.00M to $241.00M. Over 4 years (FY 2021 to FY 2025), Anti-infectives — Revenue shows a downward trend with a -3.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market demand or successful product adoption, while a decrease may indicate increased competition, patent expirations, or shifts in veterinary treatment protocols.
Detailed definition
This metric represents the total gross sales generated from the sale of anti-infective pharmaceutical products, includin...
Peer comparison
Peers in the animal health sector typically report this under therapeutic category revenue, often benchmarked against broader pharmaceutical portfolio growth rates.
zts_segment_anti_infectives_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $259.00M | $329.00M | $306.00M | $285.00M | $233.00M | $284.00M | $279.00M | $288.00M | $244.00M | $264.00M | $261.00M | $281.00M | $264.00M | $274.00M | $281.00M | $249.00M | $219.00M | $284.00M | $284.00M | $241.00M |
| QoQ Change | — | +27.0% | -7.0% | -6.9% | -18.2% | +21.9% | -1.8% | +3.2% | -15.3% | +8.2% | -1.1% | +7.7% | -6.0% | +3.8% | +2.6% | -11.4% | -12.0% | +29.7% | +0.0% | -15.1% |
| YoY Change | — | — | — | — | -10.0% | -13.7% | -8.8% | +1.1% | +4.7% | -7.0% | -6.5% | -2.4% | +8.2% | +3.8% | +7.7% | -11.4% | -17.0% | +3.6% | +1.1% | -3.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Zoetis's anti-infectives — revenue?
- Zoetis (ZTS) reported anti-infectives — revenue of $241.00M in Q1 2026.
- How has Zoetis's anti-infectives — revenue changed year-over-year?
- Zoetis's anti-infectives — revenue decreased by 3.2% year-over-year, from $249.00M to $241.00M.
- What is the long-term trend for Zoetis's anti-infectives — revenue?
- Over 4 years (2021 to 2025), Zoetis's anti-infectives — revenue has grown at a -3.9% compound annual growth rate (CAGR), from $1.22B to $1.04B.
- What does anti-infectives — revenue mean?
- The total revenue generated from the sale of animal health products used to treat or prevent infections.